Physician profile
Kara Davis
NPI 1184609117
$2,579.04
in general payments reported to CMS, 2019-2025
13 companies · $68.59 in 2025
The $68.59 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $164 · 2021: $416 · 2022: $712 · 2023: $696 · 2024: $324 · 2025: $68.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,868.81 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $214.07 | 2020-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $113.94 | 2021-2023 | |
| Janssen Biotech, INC. | $92.62 | 2019-2021 | |
| Ardelyx, INC. | $75.41 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $63.73 | 2022-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $34.74 | 2022 | |
| Shionogi INC | $29.28 | 2019 | |
| Ironwood Pharmaceuticals, INC | $28.27 | 2022-2023 | Linzess |
| Rayner Intraocular Lenses Limited | $14.87 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Johnson & Johnson Surgical Vision, INC. | $14.83 | 2023 | Tecnis Iol |
| Ucb, INC. | $14.59 | 2019 | |
| Boston Scientific Corporation | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.